Answer:
I am certain 2 of out 3 of these are part of it
Explanation:
I forgot if alveoli is part of it.
In developed countries, most individuals die at <u>hospitals</u>, whereas in developing countries most individuals die at <u>home</u>.
In excessive earnings nations the bulk of humans die of simply vast organizations of reasons: cardiovascular sickness and cancer. As cardiovascular sicknesses declined, extra humans died from cancer. The proportion of deaths from maximum different vast reasons of dying increased, too. This has brought about more range in reasons of dying. Generally, wealthier international locations have a better common existence expectancy than poorer international locations, which may be argued to be done via better requirements of living, extra powerful fitness systems, and extra assets invested in determinants of fitness (e.g. sanitation, housing, education).
Thus, option a is the correct choice.
To learn more about sickness check the link below:
brainly.com/question/25476918
#SPJ4
Answer:
The best answer to the question: A nurse is monitoring the laboratory values of a client who is receiving heparin. Which of the following values should a nurse report to the provider? would be: D: aPTT of 50 seconds.
Explanation:
Unlike Warfarin and the low-molecular weight heparin, medically speaking, the one diagnostic test that is still being used as a measure of heparin´s therapeutic achievements in a patient with a coagulopathy, is the activated partial thromboplastin time aPTT. Although the measurement in seconds, will depend on the laboratory that is doing the measuring, and despite scientific evidence that points to the fact that aPTT is not the most accurate of laboratory measurements for a patient with heparin, it is still being used today and still is the leading laboratory test for these types of patients.
Answer:
Glycosylphosphatidylinositol (About this soundpronunciation (help·info)), or glycophosphatidylinositol, or GPI in short, is a phosphoglyceride that can be attached to the C-terminus of a protein during posttranslational modification.